Illumina, Inc.
ILMN
Updated: 22/09/2026, 19:55:19
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
No summaries found.
- Share price
- $246.49
- Market cap
- $37.27B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jacob Thaysen
- Employees
- 8,600
- IPO date
- 28/07/2000
- Beta
- 1.467
- Last dividend
- $0.00
- Day range
- $234.57 – $247.69
- 52-week range
- $88.00 – $250.06
- 1-day performance
- 3.21%
- 1-year performance
- 180.10%
- Current drawdown (1Y)
- -1.43%
- CIK
- 0001110803
- CUSIP
- 452327109
- ISIN
- US4523271090
- Created
- 07/12/2025, 04:42:49
- Last update
- 22/09/2026, 19:55:19
Track Illumina, Inc. with an AI analyst
See which prediction-market events move ILMN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Illumina (ILMN): Bullish Structure Builds After Breakout
FXEmpire • STOCK • 09/06/2026, 19:10:51
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
PRNewsWire • STOCK • 08/06/2026, 11:15:00
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Zacks Investment Research • STOCK • 27/05/2026, 12:50:19
David P. King elected to Illumina's Board of Directors
PRNewsWire • STOCK • 21/05/2026, 18:15:00
Is This the Right Time to Retain ILMN Stock in Your Portfolio?
Zacks Investment Research • STOCK • 20/05/2026, 11:40:54
Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact
PRNewsWire • STOCK • 19/05/2026, 18:30:00
Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term
Zacks Investment Research • STOCK • 06/05/2026, 12:50:45
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up
Zacks Investment Research • STOCK • 01/05/2026, 12:11:21
Illumina, Inc. (ILMN) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 30/04/2026, 23:11:39
Illumina (NASDAQ: ILMN) Exceeds Revenue Estimates, Raises Guidance in Q1 2026 Earnings Report
Market Data • Market Data • 30/04/2026, 23:03:34
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research • STOCK • 30/04/2026, 23:00:20
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now?
Zacks Investment Research • STOCK • 30/04/2026, 16:50:29